Specifically, in breast cancer, emerging biomarkers such as polo-like kinase (PLK) PLK 2, PLK3, and PLK5 have been validated as significant prognostic indicators through survival analysis utilizing the Kaplan–Meier Plotter database. The gene discussed is PLK5; the disease is breast carcinoma.